As Frequent as Polyglutamine Spinocerebellar Ataxias: <scp>SCA27B</scp> in a Large German Autosomal Dominant Ataxia Cohort

Abstract

Intronic GAA repeat expansions in the fibroblast growth factor 14 gene (FGF14) have recently been shown to be a common cause of adult-onset degenerative ataxia (spinocerebellar ataxia 27B [SCA27B], MIM: 620174),1, 2 but frequencies in strictly consecutive SCA cohorts are unknown. Here we studied the relative frequencies of SCA27B in a cohort of genetically undetermined autosomal dominant cerebellar ataxia (ADCAs) and relative to other forms of genetically confirmed SCAs. We screened a consecutive cohort of 79 German patients from 51 families with genetically undetermined ADCA for the intronic FGF14 GAA repeat expansion. All index patients were negative for SCA types 1, 2, 3, 6, 7, and 17 and negative on either exome or short-read genome sequencing. Detailed inclusion criteria and methods are outlined in the Supporting Information. Twenty-Six of 51 families (26/79 patients) were found to carry a FGF14 (GAA)≥250 expansion, thus accounting for 31% of patients with ADCA (Fig. 1A). Although only expansions of at least 250 GAA repeat units were considered pathogenic1, 2 and used for the current frequency analysis, we identified one family with late-onset largely pure cerebellar ataxia, and thus compatible with SCA27B,3 in which the index patient had a repeat count of 256 GAA units, whereas her affected mother had a repeat count of 234 repeat units (Supporting Information Fig. S2). This indicates that the pathogenic threshold might be even be lower than the previously established cutoff of 250 repeat units. This hypothesis warrants further confirmation in future larger segregation and population studies. Moreover, a (GAAGGA)n repeat expansion was found in three index patients. This hexanucleotide expansion did not segregate with disease in all three families (Supporting Information Fig. S1). This provides further evidence for previous observations suggesting that non-GAA repeat expansions are unlikely pathogenic1 and warrants caution on recent discussions of its pathogenicity.4 We next compared the frequency of SCA27B with other forms of SCAs in a consecutive cohort of genetically determined patients with SCA (n = 320 index patients; for inclusion criteria, see Supporting Information Data S1). SCA27B comprised 16% (52/320) of all SCA index patients (including 36 patients without an autosomal dominant family history), representing the second most common cause of SCA in this German cohort. SCA27B had a similar frequency as the common polyglutamine SCAs SCA1 (38/320, 12%), SCA2 (28/320, 9%), SCA3 (61/320, 19%), and SCA6 (38/320, 12%) (Fig. 1B). The median age at onset in patients with SCA27B was 55 years (interquartile range [IQR], 46–64 years), which was later than in the SCA3 (median, 40 years; IQR, 31–47 years), SCA2 (median, 34 years; IQR, 26–44 years), and SCA1 patients at our center (median, 33 years; IQR, 27–37 years) and more similar to the SCA6 patients (median 56; IQR, 48–64). Our findings confirm the previously reported1-3, 5 late age at onset for SCA27B, even though our ADCA screening cohort was, unlike previous screening cohorts,1, 3, 5 not age stratified. Interestingly, one patient with SCA27B stood out with age at onset of chronic progressive gait ataxia at 27 years (size of expansion: 308 GAA repeat units). He showed a slow disease progression, as exemplified by a Scale for the assessment and rating of Ataxia (SARA) score of 15 points after 25 years of disease, consistent with previous reports of overall slow disease progression in SCA27B.3 Although the strength of this study is the investigation of a strictly consecutive cohort of autosomal dominant ataxias, it is limited by the fact that the frequency of SCA27B was studied only in a central European cohort from a single center. Future larger international multicenter studies are needed to investigate its frequency in cohorts of unexplained autosomal dominant ataxia from other regions and continents, while also analyzing and accounting for potential referral/ascertainment patterns and founder effects. Our findings highlight the immediate need to integrate SCA27B in the diagnostic workup of ADCA in clinical practice, especially because patients with SCA27B may benefit from treatment with 4-aminopyridine.3 We thank the patients and their families for participating in this study, Madeleine Wacker (Synofzik lab) for preparing some of the samples, Marie-Josée Dicaire (Brais lab) for her technical assistance, and the Centre d'Expertise et de Services Génome Québec for assistance with Sanger sequencing. Open Access funding enabled and organized by Projekt DEAL. The study was approved by the Institutional Review Board of the University of Tübingen (AZ 598/2011BO1). Written informed consent was obtained from all study participants before enrollment. Design or conceptualization of the study: H.H. and M.S. Acquisition of data: H.H., D.P., C.W., A.T., Z.F., B.B., T.H., L.S., and M.S. Analysis or interpretation of data: H.H., D.P., and M.S. Drafting or revising the manuscript for intellectual content: H.H., D.P., C.W., A.T., Z.F., B.B., T.H, L.S., and M.S. H.H., D.P., C.W., Z.F., B.B., T.H., and A.T. have no financial disclosures. L.S. has received consultancy honoraria from Novartis unrelated to this manuscript. M.S. has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, GenOrph, and AviadoBio, all unrelated to this manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Supporting Information Figure S1. Pedigrees of patients with GAAGGA hexanuleotide repeats not segregating with disease. (A) Subjects I1. and II.2 presented with late onset cerebellar ataxia. While subject II.1 carried the GAAGGA hexanuleotide repeat, subject I.1 was negative for the hexanuleotide repeat. (B) A spastic-ataxia syndrome present in subjects II.1, II.2 and III.1 led to the hypothesis of an autosomal-dominant mode of inheritance in the family, although subject II.3 was not affected. The GAAGGA repeat was present in II.2, but not in the similarly affected brother. (C) Subject II.1 presented with a congenital nystagmus, mental retardation and cerebellar ataxia, while the father showed later onset cerebellar ataxia and mild cognitive deficits. Figure S2. (A) Pedigree of an ADCA family with a segregating FGF14 GAA repeat count <250. Subect II.1 (234/149 GAA repeats) showed a slowly progressive cerebellar ataxia and signs of polyneuropathy with reduced pallesthesia, with age of onset 55 years. Subject III.1 (256/8 GAA repeats) showed pure cerebellar ataxia, with age at onset 48 years. Whereas the pathogenic threshold of SCA27B is currently thought to be >250 GAA repeats, this observation might indicate a lower threshold, possibly at 230 repeats. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Topics & Concepts